Navigation Links
Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey
Date:12/23/2009

EXTON, Pa., Dec. 23 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends®: Simponi and Cimzia report. The survey was completed by U.S. Rheumatologists (n=77) in late November 2009. BioTrends also conducted qualitative interviews with a subset (n=20) of the survey respondents to get an in-depth view of the sales and marketing messages being employed to differentiate the products. Over the course of the six month study over 300 Rheumatologists were interviewed about their reception to these new agents.

Awareness of both new TNF antagonists was nearly universal among the respondents. The initial favorability rating noted in baseline research in May 2009 for Centocor's Simponi decreased during subsequent waves of research and now trails UCB's Cimzia in both favorability and interest in learning more about these newest agents. The initial favorability rating for Cimzia has risen from the 31% reported in the two prior waves to 48% in this final wave of research coupled with a significant increase in familiarity with the product as well.

Cimzia has made significant gains, with new product share now split between these once-monthly products. Consistent with prior waves of research, Rheumatologists indicate that over 40% of their current patients on these newest TNF agents were switched from the current market share leaders Enbrel and Humira. Although the surveyed Rheumatologists perceive Simponi and Cimzia to be extremely similar, there have been a few areas of differentiation that have started to emerge.

Among Rheumatologists who have used the new anti-TNF products, overall satisfaction has increased to 60% with Simponi and 50% with Cimzia. While both Simponi and Cimzia are expected to gain market share in the next six months, the combined share of the two agents is not expected to exceed 12% of the biologic share in Rheumatoid Arthriti
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
7. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
8. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
9. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
10. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
11. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Concord ... "Company") (NYSE: CCM ), a leading specialty ... largest network of radiotherapy and diagnostic imaging centers ... the signing of a purchase agreement under which ... owned subsidiary of the Company, agreed to acquire ...
(Date:3/26/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... Omega-3 therapies for cardiovascular disease and overall health, announced ... shares of the Corporation (the "Common Shares"). The Common ... December 5 th , 2014 to March 4 th ... due on or before April 1, 2015. Interest on ...
(Date:3/26/2015)... BOTHELL, Wash. and VANCOUVER, British Columbia, March 26, ... ) today provided a summary of clinical developments ... financial results. Clinical Developments and ... December 2014, OncoGenex and Teva agreed to negotiate ... rights to OncoGenex. Negotiations of the final termination ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... today released a letter from its President Mario H. Lopez, ... dispute. At a critical time in our nation,s ... in danger of having health care choices severely affected by ... The text of the letter follows: ...
... KNSY ) today announced that it has agreed ... an attempt to resolve disputes over royalty payments to Kensey ... as other related claims. Kensey Nash has repeatedly advised St. ... should since 2007 have been paid, at a rate of ...
Cached Medicine Technology:Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 2Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 3Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 4
(Date:3/27/2015)... 2015 On March 19, 2015, ... Detroit Lions wide receiver Herman Moore, hosted “Fighting ... on substance abuse, treatment options and the recent ... were pastors, ministers and bishops from local churches ... guests. , “Our ‘Fighting Addiction Together’ luncheon was ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
(Date:3/27/2015)... Orange, CT (PRWEB) March 27, 2015 Trail ... go, after a workout, on weekend hikes and during the ... health benefits. Aurora Natural is proud to introduce a new ... your taste buds. Deliciously rich and flavorful selections packed with ... nuts, seeds, dried fruit and grains that add protein and ...
(Date:3/27/2015)... Jersey (PRWEB) March 27, 2015 Airy ... has released the official music video for her debut ... , Combining live-action and abstract styling effects, the ... be viewed on YouTube, Vimeo, and assorted outlets. It ... the development of an expanding full-scale marketing strategy. The ...
(Date:3/27/2015)... 27, 2015 Yisrayl Hawkins, Pastor and Overseer ... only way to live in Peace is through the Laws ... article published this week. , The article titled, “Yahweh’s Way-The ... mankind and how straying away from the original biblical instructions ... the system that has been created in the world is ...
Breaking Medicine News(10 mins):Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:The World Does Not Have to Continue in Misery, Says Yisrayl Hawkins in New Article 2
... Va. A study published in the December issue ... positron emission tomography/computed tomography (PET/CT) scans as a potentially ... patients treated with radiofrequency ablation (RFA). RFA, which uses ... used as an alternative treatment for patients unable to ...
... HealthDay Reporter , MONDAY, Dec. 6 (HealthDay News) -- ... reduced the chances of getting melanoma by half, a new study ... adults ages 25 to 75 into two groups. One group was ... and arms for five years between 1992 and 1996. The other ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Dec. ... to help doctors diagnose and treat food allergies was released ... Diseases (NIAID). In addition to recommending that doctors ... food allergy is suspected, the guidelines also try to help ...
... your screening mammogram during the first week of your ... accurate for pre-menopausal women who choose to have regular ... December 3 in Radiology by Diana Miglioretti, ... Dr. Miglioretti and her co-authors are working ...
... December 6 2010 -- An expansion of soybean ... been grown can be problematic for some farmers. Soils ... and/or magnesium carbonate are notoriously iron deficient. Iron deficient ... to reduce soy bean production by 12.5 million bushels ...
... to help chronic myeloid leukemia patients who are out of ... or because their cancer cells have a mutation that makes ... Annual Meeting of the American Society of Hematology. In ... or complete hematologic responses (absence of CML cells in the ...
Cached Medicine News:Health News:Fewer guessing games for lung cancer patients 2Health News:Daily Sunscreen Use Does Protect from Melanoma, Study Finds 2Health News:Daily Sunscreen Use Does Protect from Melanoma, Study Finds 3Health News:New Guidelines Aid in Diagnosis of Food Allergies 2Health News:New Guidelines Aid in Diagnosis of Food Allergies 3Health News:Mammogram sensitivity depends on menstrual cycle 2Health News:Mammogram sensitivity depends on menstrual cycle 3Health News:Iron deficiency in soil threatens soybean production 2Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2
Inquire...
... calibration mass for convenient Touch-key ... Fully Automatic Self-Calibration at designated ... are detected, or touch-key calibration ... Interface, Shimadzu WindowsDirect communication function. ...
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
... unique DNA sequencing reagents including linear ... and cyanine-based infrared dyes- coupled with online ... ore meaningful raw data, and higher-quality final ... CEQ 8800 to resolve complex sequences, filling ...
Medicine Products: